Gastrointestinal cancers in the era of theranostics: Updates and future perspectives

Ghosn, Marwan; Kourié, Hampig Raphaël; Tabchi, Samer

doi:10.3748/wjg.v21.i28.8473

Cited by 7 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cell membrane camouflaged biomimetic nanoparticles as examples of theranostics are recently reviewed in ref [ 138 ]. Also theranostics applied for gastrointestinal cancers are fully described in ref [ 139 ].…”

Section: Advanced Strategies For Crc Drug Deliverymentioning

confidence: 99%

Recent advances in targeted drug delivery systems for resistant colorectal cancer

et al. 2022

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the deadliest cancers in the world, the incidences and morality rate are rising and poses an important threat to the public health. It is known that multiple drug resistance (MDR) is one of the major obstacles in CRC treatment. Tumor microenvironment plus genomic instability, tumor derived exosomes (TDE), cancer stem cells (CSCs), circulating tumor cells (CTCs), cell-free DNA (cfDNA), as well as cellular signaling pathways are important issues regarding resistance. Since non-targeted therapy causes toxicity, diverse side effects, and undesired efficacy, targeted therapy with contribution of various carriers has been developed to address the mentioned shortcomings. In this paper the underlying causes of MDR and then various targeting strategies including exosomes, liposomes, hydrogels, cell-based carriers and theranostics which are utilized to overcome therapeutic resistance will be described. We also discuss implication of emerging approaches involving single cell approaches and computer-aided drug delivery with high potential for meeting CRC medical needs.

show abstract

Section: Advanced Strategies For Crc Drug Deliverymentioning

confidence: 99%

Recent advances in targeted drug delivery systems for resistant colorectal cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Their effectiveness of chemotherapy remains limited due to the intrinsic build-up of resistance of cancer cells to chemotherapy drugs, dose-limiting toxicities and other major side effects. New strategies to overcome these issues are being developed, one of which is cancer nanomedicine, a rapidly developing interdisciplinary research field [90].…”

Section: Dendrimer Nanoparticles In Crcmentioning

confidence: 99%

Dendrimer nanoparticles for colorectal cancer applications

2020

View full text Add to dashboard Cite

show abstract

“…Surgery, targeted therapy, chemotherapy, and radiation therapy are among the therapeutic options used to extend a patient's life and improve their quality of life [1,2]. Multidrug resistance is a major issue in antitumor chemotherapy (MDR) [17][18][19][20]. The distribution of available chemotherapeutic medicines to target-specific locations is a big difficulty [21][22][23].…”

Section: Introductionmentioning

confidence: 99%

A review on nanoparticles targeting cervical and endometrial cancer

Pepakayala¹,

Nalli²,

Ravi³

et al. 2022

World J. Bio. Pharm. Health Sci.

View full text Add to dashboard Cite

The two most frequent gynecological cancers in women globally are cervical and endometrial cancers. Despite the fact that a variety of medications have been created for treatment, they frequently result in a number of negative side effects, toxicity, and multidrug resistance (MDR). Despite the fact that surgery and chemo radiotherapy can cure 80–95 percent of women with early-stage cancer, recurring and metastatic disease remains a leading cause of cancer death. To address this, scientists have taken advantage of the benefits afforded by nano systems, such as nanocarriers in the fields of tumor targeting, increased drug accumulation in tumors, and so on. The major characteristics of this system include biodegradability, biocompatibility, non-toxicity, prolonged circulation, and a large payload range of a therapeutic drug. Anticancer treatment side effects can be decreased by encapsulating the drug and delivering it directly to the cancer site. Drug release at cancer locations using stimuli responsive nanocarriers is effective for achieving target-specific delivery. When compared to the conventional system, these methods exhibit improved ability to target malignant cells without harming healthy cells and offer the promise for advanced cancer therapy. Recent breakthroughs in intrinsic and extrinsic-stimulus sensitive nanomaterial systems for drug administration in cancer therapy, as well as other polymeric nano particles employed in cancer therapy, are discussed in this study.

show abstract

Gastrointestinal cancers in the era of theranostics: Updates and future perspectives

Cited by 7 publications

References 26 publications

Recent advances in targeted drug delivery systems for resistant colorectal cancer

Recent advances in targeted drug delivery systems for resistant colorectal cancer

Dendrimer nanoparticles for colorectal cancer applications

A review on nanoparticles targeting cervical and endometrial cancer

Contact Info

Product

Resources

About